Flublok influenza vaccine now approved for adults 18 and older
FDA has approved Flublok (Protein Sciences) recombinant influenza vaccine for all adults aged 18 years and older. Previously, Flublok was indicated for adults aged 18 to 49 years.
FDA has approved Flublok (Protein Sciences) recombinant influenza vaccine for all adults aged 18 years and older. Previously, Flublok was indicated for adults aged 18 to 49 years.
“This makes it easier for decision-makers to offer the product because it has broader use and is more applicable to the populations they serve,” according to Rachael S. Felberbaum, PhD, Protein Sciences spokesperson.
Flu vaccine: What you need to know
“Many people do not like the features of traditional flu vaccines. Flublok overcomes many of the objections to vaccination and increases vaccine uptake,” Felberbaum said. “Influenza vaccination is an important quality measure hospitals and healthcare professionals take to prevent illness and promote health and well-being for their patients and employees.”
Flublok is the only 100% egg-free flu vaccine available and is recommended by the Advisory Committee on Immunization Practices (ACIP) for the egg-allergic population and non-allergic individuals.
“We have seen higher antibody levels against certain strains of influenza in older adults vaccinated with Flublok,” said Felberbaum. “The majority of the time the flu season peaks in February, so now is a good time for people to get vaccinated. For now, flu activity in the United States remains low but it is expected to increase in the coming weeks. For all vaccines, it takes about 2 weeks after vaccination for antibody levels to build to the level where individuals are protected.”
Earlier this year FDA approved a shelf-life extension for Flublok to 6 months.
Recommendations regarding the 2015-2016 flu vaccine composition will be made by the World Health Organization and FDA in late February 2015.
Related
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
